S2104 Study
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
GENDER: All
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
Learn More About This Research Study
To learn more about this study, please call study coordinator, Debbie Donohue at 216-220-6456 or complete the online form below.
Study Purpose
The purpose of this study is to evaluate recurrence-free survival in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.
Who Can Participate
Participants 18 years old and older may be eligibile if the patient has high-risk pancreatic neuroendocrine tumors. Patient may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of the pNET resection. Eligible patients cannot currently have liver metastasis.